

SPINE SAFETY WARNING:

**Information for Healthcare Professionals:
Important Revisions to the Prescribing Information for
Doral® (quazepam tablets, USP)**

According to MedWatch, modifications have been made to the WARNINGS and PRECAUTIONS sections of Doral® (quazepam tablets, USP) labeling. The revised WARNINGS section addresses severe anaphylactic and anaphylactoid reactions. The revised PRECAUTIONS section provides information for patients about possible emergence of “sleep-driving” and other complex behaviors.

The complete MedWatch Safety Labeling Changes, including a link to prescribing information and the new medication guide, are available at:

<http://www.fda.gov/medwatch/SAFETY/2007/oct07.htm>

The North American Spine Society is committed to quality patient care through promotion of patient safety and prevention of medical errors. NASS monitors a variety of government and other resources for patient safety related notices that may be useful to our members. Information from these notices is also archived on the NASS Web site at

<http://www.spine.org/Pages/PracticePolicy/ClinicalCare/SpineSafetyAlerts/Default.aspx>. This information is provided as a service for information and education only.